Efficacy and Safety of Fast-Acting Insulin Aspart in People with Type 1 Diabetes Using Carbohydrate Counting: A Post Hoc Analysis ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-04-04

AUTHORS

Ludger Rose, Takashi Kadowaki, Thomas R Pieber, Kristine Buchholtz, Magnus Ekelund, Anders Gorst-Rasmussen, Athena Philis-Tsimikas

ABSTRACT

INTRODUCTION: Insulin dosing based on carbohydrate counting is the gold standard for improving glycaemic control in type 1 diabetes (T1D). This post hoc analysis aimed to explore the efficacy and safety of fast-acting insulin aspart (faster aspart) according to bolus dose adjustment method in people with T1D. METHODS: Post hoc analysis of two 26-week, treat-to-target, randomised trials investigating treatment with double-blind mealtime faster aspart, insulin aspart (IAsp), or open-label post-meal faster aspart (onset 1, n = 1143; onset 8, n = 1025). Participants with previous experience continued carbohydrate counting (onset 1, n = 669 [58.5%]; onset 8, n = 428 [41.8%]), while remaining participants used a bolus algorithm. RESULTS: In onset 1, HbA1c reduction was statistically significantly in favour of mealtime faster aspart versus IAsp with carbohydrate counting (estimated treatment difference [ETD 95% CI] - 0.19% [- 0.30; - 0.09]; - 2.08 mmol/mol [- 3.23; - 0.93]). In onset 8, there was no statistically significant difference in HbA1c reduction with either dose adjustment method, although a trend towards improved HbA1c was observed for mealtime faster aspart with carbohydrate counting (ETD - 0.14% [- 0.28; 0.003]; - 1.53 mmol/mol [- 3.10; 0.04]). In both trials, bolus insulin doses and overall rates of severe or blood glucose-confirmed hypoglycaemia were similar between treatments across dose adjustment methods. CONCLUSION: For people with T1D using carbohydrate counting, mealtime faster aspart may offer improved glycaemic control versus IAsp, with similar insulin dose and weight gain and no increased risk of hypoglycaemia. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01831765 (onset 1) and NCT02500706 (onset 8). FUNDING: Novo Nordisk. More... »

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s13300-019-0608-4

DOI

http://dx.doi.org/10.1007/s13300-019-0608-4

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1113185322

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30949906


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Institute of Diabetes Research, Hohenzollernring 70, 48145, M\u00fcnster, Germany. l.rose@diabetes-muenster.de."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rose", 
        "givenName": "Ludger", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Tokyo", 
          "id": "https://www.grid.ac/institutes/grid.26999.3d", 
          "name": [
            "Department of Prevention of Diabetes and Lifestyle-Related Diseases, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.", 
            "Department of Metabolism and Nutrition, Teikyo University Hospital Mizonokuchi, 5 Chome-1-1 Futago, Takatsu Ward, Kawasaki, Kanagawa, 213-8507, Japan."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kadowaki", 
        "givenName": "Takashi", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical University of Graz", 
          "id": "https://www.grid.ac/institutes/grid.11598.34", 
          "name": [
            "Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pieber", 
        "givenName": "Thomas R", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novo Nordisk (Denmark)", 
          "id": "https://www.grid.ac/institutes/grid.425956.9", 
          "name": [
            "Novo Nordisk A/S, Vandt\u00e5rnsvej 114, 2860, S\u00f8borg, Denmark."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Buchholtz", 
        "givenName": "Kristine", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novo Nordisk (Denmark)", 
          "id": "https://www.grid.ac/institutes/grid.425956.9", 
          "name": [
            "Novo Nordisk A/S, Vandt\u00e5rnsvej 114, 2860, S\u00f8borg, Denmark."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ekelund", 
        "givenName": "Magnus", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novo Nordisk (Denmark)", 
          "id": "https://www.grid.ac/institutes/grid.425956.9", 
          "name": [
            "Novo Nordisk A/S, Vandt\u00e5rnsvej 114, 2860, S\u00f8borg, Denmark."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gorst-Rasmussen", 
        "givenName": "Anders", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Scripps Whittier Diabetes Institute", 
          "id": "https://www.grid.ac/institutes/grid.288434.1", 
          "name": [
            "Scripps Whittier Diabetes Institute, Scripps Health, 10140 Campus Point Drive Suite 200, San Diego, CA, 92121, USA."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Philis-Tsimikas", 
        "givenName": "Athena", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/j.diabres.2012.10.024", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001231814"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s2213-8587(13)70090-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001900895"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00592-014-0604-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003769196", 
          "https://doi.org/10.1007/s00592-014-0604-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/dc15-0078", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003937589"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1463-1326.2012.01580.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004224811"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/193229680700100102", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005464558"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/193229680700100102", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005464558"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1463-1326.2000.00107.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033055450"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-005-1905-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035194558", 
          "https://doi.org/10.1007/s00125-005-1905-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-005-1905-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035194558", 
          "https://doi.org/10.1007/s00125-005-1905-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-005-1905-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035194558", 
          "https://doi.org/10.1007/s00125-005-1905-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.diabres.2010.03.017", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038122779"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/srep37067", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049548806", 
          "https://doi.org/10.1038/srep37067"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/dom.12501", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049758490"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13690-015-0088-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050784376", 
          "https://doi.org/10.1186/s13690-015-0088-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/bmj.325.7367.746", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051193619"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1210/jc.2012-4127", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064294073"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diab.44.8.968", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1070737629"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diacare.18.5.625", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1070746709"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diaclin.34.3.142", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1070750271"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40262-017-0514-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083842737", 
          "https://doi.org/10.1007/s40262-017-0514-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40262-017-0514-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083842737", 
          "https://doi.org/10.1007/s40262-017-0514-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/dc16-1771", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084404991"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1615692", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085989847"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.2017.7115", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090332621"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/dom.13205", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100242863"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/dme.13603", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101033394"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.20945/2359-3997000000045", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1104167636"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/dom.13545", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1107258711"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/dom.13545", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1107258711"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-04-04", 
    "datePublishedReg": "2019-04-04", 
    "description": "INTRODUCTION: Insulin dosing based on carbohydrate counting is the gold standard for improving glycaemic control in type 1 diabetes (T1D). This post hoc analysis aimed to explore the efficacy and safety of fast-acting insulin aspart (faster aspart) according to bolus dose adjustment method in people with T1D.\nMETHODS: Post hoc analysis of two 26-week, treat-to-target, randomised trials investigating treatment with double-blind mealtime faster aspart, insulin aspart (IAsp), or open-label post-meal faster aspart (onset 1, n\u2009=\u20091143; onset 8, n\u2009=\u20091025). Participants with previous experience continued carbohydrate counting (onset 1, n\u2009=\u2009669 [58.5%]; onset 8, n\u2009=\u2009428 [41.8%]), while remaining participants used a bolus algorithm.\nRESULTS: In onset 1, HbA1c reduction was statistically significantly in favour of mealtime faster aspart versus IAsp with carbohydrate counting (estimated treatment difference [ETD 95% CI] - 0.19% [-\u20090.30;\u2009-\u20090.09]; - 2.08\u00a0mmol/mol [- 3.23; - 0.93]). In onset 8, there was no statistically significant difference in HbA1c reduction with either dose adjustment method, although a trend towards improved HbA1c was observed for mealtime faster aspart with carbohydrate counting (ETD - 0.14% [-\u20090.28; 0.003]; - 1.53\u00a0mmol/mol [- 3.10; 0.04]). In both trials, bolus insulin doses and overall rates of severe or blood glucose-confirmed hypoglycaemia were similar between treatments across dose adjustment methods.\nCONCLUSION: For people with T1D using carbohydrate counting, mealtime faster aspart may offer improved glycaemic control versus IAsp, with similar insulin dose and weight gain and no increased risk of hypoglycaemia.\nTRIAL REGISTRATION: ClinicalTrials.gov: NCT01831765 (onset 1) and NCT02500706 (onset 8).\nFUNDING: Novo Nordisk.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s13300-019-0608-4", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1044057", 
        "issn": [
          "1869-6953", 
          "1869-6961"
        ], 
        "name": "Diabetes Therapy", 
        "type": "Periodical"
      }
    ], 
    "name": "Efficacy and Safety of Fast-Acting Insulin Aspart in People with Type 1 Diabetes Using Carbohydrate Counting: A Post Hoc Analysis of Two Randomised Controlled Trials.", 
    "productId": [
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30949906"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101539025"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s13300-019-0608-4"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1113185322"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s13300-019-0608-4", 
      "https://app.dimensions.ai/details/publication/pub.1113185322"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T14:19", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000372_0000000372/records_117117_00000003.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/s13300-019-0608-4"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13300-019-0608-4'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13300-019-0608-4'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13300-019-0608-4'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13300-019-0608-4'


 

This table displays all metadata directly associated to this object as RDF triples.

185 TRIPLES      20 PREDICATES      49 URIs      16 LITERALS      6 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s13300-019-0608-4 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N4387c69032154636a6c330b3900e5413
4 schema:citation sg:pub.10.1007/s00125-005-1905-1
5 sg:pub.10.1007/s00592-014-0604-0
6 sg:pub.10.1007/s40262-017-0514-8
7 sg:pub.10.1038/srep37067
8 sg:pub.10.1186/s13690-015-0088-6
9 https://doi.org/10.1001/jama.2017.7115
10 https://doi.org/10.1016/j.diabres.2010.03.017
11 https://doi.org/10.1016/j.diabres.2012.10.024
12 https://doi.org/10.1016/s2213-8587(13)70090-1
13 https://doi.org/10.1046/j.1463-1326.2000.00107.x
14 https://doi.org/10.1056/nejmoa1615692
15 https://doi.org/10.1111/dme.13603
16 https://doi.org/10.1111/dom.12501
17 https://doi.org/10.1111/dom.13205
18 https://doi.org/10.1111/dom.13545
19 https://doi.org/10.1111/j.1463-1326.2012.01580.x
20 https://doi.org/10.1136/bmj.325.7367.746
21 https://doi.org/10.1177/193229680700100102
22 https://doi.org/10.1210/jc.2012-4127
23 https://doi.org/10.20945/2359-3997000000045
24 https://doi.org/10.2337/dc15-0078
25 https://doi.org/10.2337/dc16-1771
26 https://doi.org/10.2337/diab.44.8.968
27 https://doi.org/10.2337/diacare.18.5.625
28 https://doi.org/10.2337/diaclin.34.3.142
29 schema:datePublished 2019-04-04
30 schema:datePublishedReg 2019-04-04
31 schema:description INTRODUCTION: Insulin dosing based on carbohydrate counting is the gold standard for improving glycaemic control in type 1 diabetes (T1D). This post hoc analysis aimed to explore the efficacy and safety of fast-acting insulin aspart (faster aspart) according to bolus dose adjustment method in people with T1D. METHODS: Post hoc analysis of two 26-week, treat-to-target, randomised trials investigating treatment with double-blind mealtime faster aspart, insulin aspart (IAsp), or open-label post-meal faster aspart (onset 1, n = 1143; onset 8, n = 1025). Participants with previous experience continued carbohydrate counting (onset 1, n = 669 [58.5%]; onset 8, n = 428 [41.8%]), while remaining participants used a bolus algorithm. RESULTS: In onset 1, HbA1c reduction was statistically significantly in favour of mealtime faster aspart versus IAsp with carbohydrate counting (estimated treatment difference [ETD 95% CI] - 0.19% [- 0.30; - 0.09]; - 2.08 mmol/mol [- 3.23; - 0.93]). In onset 8, there was no statistically significant difference in HbA1c reduction with either dose adjustment method, although a trend towards improved HbA1c was observed for mealtime faster aspart with carbohydrate counting (ETD - 0.14% [- 0.28; 0.003]; - 1.53 mmol/mol [- 3.10; 0.04]). In both trials, bolus insulin doses and overall rates of severe or blood glucose-confirmed hypoglycaemia were similar between treatments across dose adjustment methods. CONCLUSION: For people with T1D using carbohydrate counting, mealtime faster aspart may offer improved glycaemic control versus IAsp, with similar insulin dose and weight gain and no increased risk of hypoglycaemia. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01831765 (onset 1) and NCT02500706 (onset 8). FUNDING: Novo Nordisk.
32 schema:genre research_article
33 schema:inLanguage en
34 schema:isAccessibleForFree false
35 schema:isPartOf sg:journal.1044057
36 schema:name Efficacy and Safety of Fast-Acting Insulin Aspart in People with Type 1 Diabetes Using Carbohydrate Counting: A Post Hoc Analysis of Two Randomised Controlled Trials.
37 schema:productId N4a8ba41c608a40cf9618603c0e3d1e9d
38 N7fa02197e10b42978e535acb533bb3e6
39 Nab2485a9150a484e90ff8c83fa4bb796
40 Nb1c4ddc2157c40e49c81ba2c90d13c10
41 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113185322
42 https://doi.org/10.1007/s13300-019-0608-4
43 schema:sdDatePublished 2019-04-11T14:19
44 schema:sdLicense https://scigraph.springernature.com/explorer/license/
45 schema:sdPublisher Nbaf65c07effb43b598a46d47e73268af
46 schema:url http://link.springer.com/10.1007/s13300-019-0608-4
47 sgo:license sg:explorer/license/
48 sgo:sdDataset articles
49 rdf:type schema:ScholarlyArticle
50 N048bceb5ba5d45c599f70c8e44db3c03 rdf:first Nc473e68918d14ddfbcec1ce83439f741
51 rdf:rest Nc156e6967d0742ba91387a561593bfc5
52 N0a72d2f924cb43ecb2c52ced72ec685a rdf:first N94dae45c61ed498c8bf5c50647435ef6
53 rdf:rest rdf:nil
54 N283e77dfa69b4fa3951d9fa7280a6c68 schema:name Institute of Diabetes Research, Hohenzollernring 70, 48145, Münster, Germany. l.rose@diabetes-muenster.de.
55 rdf:type schema:Organization
56 N3c75b3c5fcc1437ab595dff2a17b0cd6 rdf:first N9c45c5391a94488bbeea88761c3bb378
57 rdf:rest N0a72d2f924cb43ecb2c52ced72ec685a
58 N4387c69032154636a6c330b3900e5413 rdf:first N681a05731c6444dba081ff2d57dd7ac6
59 rdf:rest N048bceb5ba5d45c599f70c8e44db3c03
60 N4a8ba41c608a40cf9618603c0e3d1e9d schema:name doi
61 schema:value 10.1007/s13300-019-0608-4
62 rdf:type schema:PropertyValue
63 N681a05731c6444dba081ff2d57dd7ac6 schema:affiliation N283e77dfa69b4fa3951d9fa7280a6c68
64 schema:familyName Rose
65 schema:givenName Ludger
66 rdf:type schema:Person
67 N6b4feb63b1f7464f801135fcbf47888e rdf:first Nb47602c2602c462fb5d6e678ff2c6133
68 rdf:rest Nc58b7c685b3c484d8a33d886fdeea644
69 N7fa02197e10b42978e535acb533bb3e6 schema:name pubmed_id
70 schema:value 30949906
71 rdf:type schema:PropertyValue
72 N8a8f26a232554924bf8e16934cfc4e02 schema:affiliation https://www.grid.ac/institutes/grid.425956.9
73 schema:familyName Ekelund
74 schema:givenName Magnus
75 rdf:type schema:Person
76 N94dae45c61ed498c8bf5c50647435ef6 schema:affiliation https://www.grid.ac/institutes/grid.288434.1
77 schema:familyName Philis-Tsimikas
78 schema:givenName Athena
79 rdf:type schema:Person
80 N9c45c5391a94488bbeea88761c3bb378 schema:affiliation https://www.grid.ac/institutes/grid.425956.9
81 schema:familyName Gorst-Rasmussen
82 schema:givenName Anders
83 rdf:type schema:Person
84 Nab2485a9150a484e90ff8c83fa4bb796 schema:name nlm_unique_id
85 schema:value 101539025
86 rdf:type schema:PropertyValue
87 Nb1c4ddc2157c40e49c81ba2c90d13c10 schema:name dimensions_id
88 schema:value pub.1113185322
89 rdf:type schema:PropertyValue
90 Nb47602c2602c462fb5d6e678ff2c6133 schema:affiliation https://www.grid.ac/institutes/grid.425956.9
91 schema:familyName Buchholtz
92 schema:givenName Kristine
93 rdf:type schema:Person
94 Nbaf65c07effb43b598a46d47e73268af schema:name Springer Nature - SN SciGraph project
95 rdf:type schema:Organization
96 Nc156e6967d0742ba91387a561593bfc5 rdf:first Nf939a4fb60ef4c53a7a4b71554f886c4
97 rdf:rest N6b4feb63b1f7464f801135fcbf47888e
98 Nc473e68918d14ddfbcec1ce83439f741 schema:affiliation https://www.grid.ac/institutes/grid.26999.3d
99 schema:familyName Kadowaki
100 schema:givenName Takashi
101 rdf:type schema:Person
102 Nc58b7c685b3c484d8a33d886fdeea644 rdf:first N8a8f26a232554924bf8e16934cfc4e02
103 rdf:rest N3c75b3c5fcc1437ab595dff2a17b0cd6
104 Nf939a4fb60ef4c53a7a4b71554f886c4 schema:affiliation https://www.grid.ac/institutes/grid.11598.34
105 schema:familyName Pieber
106 schema:givenName Thomas R
107 rdf:type schema:Person
108 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
109 schema:name Medical and Health Sciences
110 rdf:type schema:DefinedTerm
111 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
112 schema:name Clinical Sciences
113 rdf:type schema:DefinedTerm
114 sg:journal.1044057 schema:issn 1869-6953
115 1869-6961
116 schema:name Diabetes Therapy
117 rdf:type schema:Periodical
118 sg:pub.10.1007/s00125-005-1905-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035194558
119 https://doi.org/10.1007/s00125-005-1905-1
120 rdf:type schema:CreativeWork
121 sg:pub.10.1007/s00592-014-0604-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003769196
122 https://doi.org/10.1007/s00592-014-0604-0
123 rdf:type schema:CreativeWork
124 sg:pub.10.1007/s40262-017-0514-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083842737
125 https://doi.org/10.1007/s40262-017-0514-8
126 rdf:type schema:CreativeWork
127 sg:pub.10.1038/srep37067 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049548806
128 https://doi.org/10.1038/srep37067
129 rdf:type schema:CreativeWork
130 sg:pub.10.1186/s13690-015-0088-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050784376
131 https://doi.org/10.1186/s13690-015-0088-6
132 rdf:type schema:CreativeWork
133 https://doi.org/10.1001/jama.2017.7115 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090332621
134 rdf:type schema:CreativeWork
135 https://doi.org/10.1016/j.diabres.2010.03.017 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038122779
136 rdf:type schema:CreativeWork
137 https://doi.org/10.1016/j.diabres.2012.10.024 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001231814
138 rdf:type schema:CreativeWork
139 https://doi.org/10.1016/s2213-8587(13)70090-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001900895
140 rdf:type schema:CreativeWork
141 https://doi.org/10.1046/j.1463-1326.2000.00107.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1033055450
142 rdf:type schema:CreativeWork
143 https://doi.org/10.1056/nejmoa1615692 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085989847
144 rdf:type schema:CreativeWork
145 https://doi.org/10.1111/dme.13603 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101033394
146 rdf:type schema:CreativeWork
147 https://doi.org/10.1111/dom.12501 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049758490
148 rdf:type schema:CreativeWork
149 https://doi.org/10.1111/dom.13205 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100242863
150 rdf:type schema:CreativeWork
151 https://doi.org/10.1111/dom.13545 schema:sameAs https://app.dimensions.ai/details/publication/pub.1107258711
152 rdf:type schema:CreativeWork
153 https://doi.org/10.1111/j.1463-1326.2012.01580.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1004224811
154 rdf:type schema:CreativeWork
155 https://doi.org/10.1136/bmj.325.7367.746 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051193619
156 rdf:type schema:CreativeWork
157 https://doi.org/10.1177/193229680700100102 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005464558
158 rdf:type schema:CreativeWork
159 https://doi.org/10.1210/jc.2012-4127 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064294073
160 rdf:type schema:CreativeWork
161 https://doi.org/10.20945/2359-3997000000045 schema:sameAs https://app.dimensions.ai/details/publication/pub.1104167636
162 rdf:type schema:CreativeWork
163 https://doi.org/10.2337/dc15-0078 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003937589
164 rdf:type schema:CreativeWork
165 https://doi.org/10.2337/dc16-1771 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084404991
166 rdf:type schema:CreativeWork
167 https://doi.org/10.2337/diab.44.8.968 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070737629
168 rdf:type schema:CreativeWork
169 https://doi.org/10.2337/diacare.18.5.625 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070746709
170 rdf:type schema:CreativeWork
171 https://doi.org/10.2337/diaclin.34.3.142 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070750271
172 rdf:type schema:CreativeWork
173 https://www.grid.ac/institutes/grid.11598.34 schema:alternateName Medical University of Graz
174 schema:name Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria.
175 rdf:type schema:Organization
176 https://www.grid.ac/institutes/grid.26999.3d schema:alternateName University of Tokyo
177 schema:name Department of Metabolism and Nutrition, Teikyo University Hospital Mizonokuchi, 5 Chome-1-1 Futago, Takatsu Ward, Kawasaki, Kanagawa, 213-8507, Japan.
178 Department of Prevention of Diabetes and Lifestyle-Related Diseases, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
179 rdf:type schema:Organization
180 https://www.grid.ac/institutes/grid.288434.1 schema:alternateName Scripps Whittier Diabetes Institute
181 schema:name Scripps Whittier Diabetes Institute, Scripps Health, 10140 Campus Point Drive Suite 200, San Diego, CA, 92121, USA.
182 rdf:type schema:Organization
183 https://www.grid.ac/institutes/grid.425956.9 schema:alternateName Novo Nordisk (Denmark)
184 schema:name Novo Nordisk A/S, Vandtårnsvej 114, 2860, Søborg, Denmark.
185 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...